Antiviral Therapy

More documents

Recommendations

Info

PEG-INTERFERON • 40 kDa branched chain polyethylene glycol covalently bonded to interferon • Results in sustained delivery and reduced clearance of interferon -Allows for once weekly dosing • Decreases the development of interferon resistance • Similar safety profile re: non-PEG interferon
LAMIVUDINE Pyrimidine nucleoside = cytosine analogue Pharmacokinetics • Dose form - Oral • High oral bioavailability (86%) • Clearance – Half-life 5-7 hr
Page 1 and 2: Antiviral Therapy David Andes, M.D.
Page 3 and 4: VIRUS CHARACTERISTICS • Consist o
Page 5 and 6: Immunoglobulin POTENTIAL DRUG TARGE
Page 7 and 8: PROBLEMS WITH ANTIVIRALS •Static
Page 9: DRUGS AVAILABLE FOR •Respiratory
Page 12 and 13: Pharmacokinetics FAMCICLOVIR Diacet
Page 14: ACYCLOVIR - FAMCICLOVIR - VALACYCLO
Page 17 and 18: ACYCLOVIR - FAMCICLOVIR - VALACYCLO
Page 19 and 20: Indications for IV Acyclovir • Se
Page 21 and 22: Mechanism of Action Triphosphorylat
Page 23 and 24: GANCICLOVIR Toxicity • Bone marro
Page 25 and 26: FOSCARNET Trisodium phosphonoformat
Page 27 and 28: FOSCARNET Mechanism of Resistance
Page 29 and 30: Toxicity COMMON FOSCARNET • Renal
Page 31 and 32: Mechanism of Action CIDOFOVIR • C
Page 33 and 34: RIBAVIRIN • Guanosine (nucleoside
Page 35 and 36: Spectrum of Activity RIBAVIRIN •
Page 37 and 38: AMANTIDINE - RIMANTIDINE Tricyclic
Page 39 and 40: AMANTIDINE - RIMANTIDINE Spectrum o
Page 41 and 42: OSELTAMAVIR - ZAMINAVIR Sialic acid
Page 43 and 44: OSELTAMAVIR - ZAMINAVIR Mechanism o
Page 45 and 46: INTERFERON Glycoproteins = Cytokine
Page 47: INTERFERON Toxicity •Expected (oc
Page 51 and 52: Pharmacokinetics • Dose form - Or
Page 53 and 54: Clinical Cases
Page 55 and 56: Hepatitis B Virus
Page 57 and 58: Hepatocellular Carcinoma
Page 59 and 60: Management of Exposures to Hepatiti
Page 61 and 62: Clear Virus in Bloodstream • Pref
Page 63: Case Two: A 42 year old man is foun
Page 66 and 67: Therapy for Hepatitis B Infection
Page 68 and 69: Case Three (continued) The best cho
Page 70: Case Four A 19 year old man present
Page 73 and 74: Case Four (continued) As you write
Page 75: Case Five: A 72 year old man has re
Page 78 and 79: Case Five (continued): A nasopharyn
Page 80 and 81: Drugs for Influenza • Amantadine
Page 82 and 83: Drugs for Influenza • Zanamavir -
Page 84 and 85: Influenza: Rimantadine Prophylaxis
Page 86 and 87: Electron Micrograph of Herpes Simpl
Page 88 and 89: Case Six (continued) You tell her t
Page 90: Case Seven A 22 year old man presen
Page 93 and 94: Case Seven (continued) Which of the
Page 95 and 96: Case Seven (continued) The young ma
Page 97 and 98: Recurrent Genital Herpes • Recurr
Page 100 and 101:
Case Eight (continued) You are conc
Page 102:
Case Nine: A 65 year old white woma
Page 105 and 106:
Case Nine (continued): For treatmen
Page 107:
Case Ten: A 32 year old man with po
Page 110 and 111:
Case Eleven: Same 32 year old man w
Page 112 and 113:
Drugs to Treat Herpes Virus Infecti
Page 114 and 115:
Bar Entry into Host Cell • Rimant
Page 116 and 117:
Impede Gene Replication • Cidofov
Page 118 and 119:
Stop Release of Viral Progeny • O
Page 120:
CMV lacks viral TK so acyclovir is
Page 127 and 128:
Clear Virus in Bloodstream Bar Entr
Page 129 and 130:
Clear Virus in Bloodstream Bar Entr
Page 131:
POTENTIAL DRUG TARGETS Clear virus
show all

Antiviral Therapy

Create successful ePaper yourself

Delete template?

Save as template?